Naratriptan
Amerge (naratriptan) is a small molecule pharmaceutical. Naratriptan was first approved as Amerge on 1998-02-10. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1A, and 5-hydroxytryptamine receptor 1E.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Amerge (generic drugs available since 2010-07-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Naratriptan hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AMERGE | GSK | N-020763 RX | 1998-02-10 | 2 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| naratriptan | ANDA | 2022-12-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | 1 | 1 | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
| Pancytopenia | D010198 | HP_0001876 | D61.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | 1 | — | — | — | 1 | |
| Bone marrow failure disorders | D000080983 | 1 | 1 | — | — | — | 1 | ||
| Telomere shortening | D059506 | 1 | 1 | — | — | — | 1 | ||
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | 2 | — | — | — | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Hiv wasting syndrome | D019247 | EFO_0007312 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NARATRIPTAN |
| INN | naratriptan |
| Description | Naratriptan is a sulfonamide, a member of tryptamines and a heteroarylpiperidine. It has a role as a serotonergic agonist and a vasoconstrictor agent. |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1 |
Identifiers
| PDB | — |
| CAS-ID | 121679-13-8 |
| RxCUI | 141366 |
| ChEMBL ID | CHEMBL1278 |
| ChEBI ID | 7478 |
| PubChem CID | 4440 |
| DrugBank | DB00952 |
| UNII ID | QX3KXL1ZA2 (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1D
HTR1D
HTR1B
HTR1B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1F
HTR1F
HTR1A
HTR1A
HTR1E
HTR1E
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 667 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
173 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more